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Purpose: Sorafenib is recommended as the standard treatment for hepatocellular carcinoma 
(HCC) of Barcelona Clinic of Liver Cancer stage C (BCLC C). However, local treatment includ-
ing radiation therapy (LRT) is also widely administered in practice. The aim of our study was 
to define the role of LRT among BCLC C patients.
Patients and methods: Of the patients with HCC enrolled the Korean Central Cancer Registry 
from 2008 to 2014, the Korean Liver Cancer Study Group randomly extracted 10,580 patient 
data from ~50 hospitals nationwide. Among them, 3,401 patients were categorized to have BCLC 
C HCC. Among them, patients with information on initial treatments, defined as the first and 
secondary treatment within 60 days after the first treatment, were selected and classified into 
three initial treatment groups: LRT, sorafenib, and no treatment.
Results: Among 3,401 BCLC C HCC patients, 1,486 were included in the study and the remain-
ing patients were excluded as they did not meet the criteria (eg, underwent local treatments 
without radiotherapy [RT] or received chemotherapy other than sorafenib). Of these, 266 were 
assigned to LRT (17.9%), 316 to sorafenib (21.3%), and 904 to no treatment group (60.8%). 
Median survival time of the sorafenib group was shorter than that of the LRT group (3.8 vs 7.6 
months, P<0.001). In multivariable analysis, sorafenib group showed significantly higher risk 
related to mortality compared to LRT group, not only among all patients (HR: 1.50, 95% CI: 
1.23–1.84) but also between subgroup cohorts with portal invasions (1.55, 1.23–1.84), with 
lymph node metastases (2.42, 1.53–3.83), without distant metastases (1.43, 1.10–1.87), and 
with distant metastases (1.57, 1.13–2.19). Additionally, no treatment group showed the worst 
survival among the three treatment groups not only in all patients, but also in all subgroups of 
patients (P<0.001 in all).
Conclusion: LRT as an initial treatment showed survival benefit as compared to sorafenib in 
HCC patients of BCLC C.
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Introduction
Hepatocellular carcinoma (HCC) is one of the common cancers worldwide and the most 
common primary liver malignancy.1 Unfortunately, >50% of HCC cases have advanced 
stage of the disease and show a dismal prognosis with median overall survival (OS) 
of below 12 months.2 Generally, cancer staging systems provide guidelines for tumor 
assessment, severity, treatment, and prognosis. Among various staging systems for 
HCC, the Barcelona Clinic of Liver Cancer (BCLC) classification, categorizing HCC 
as A (early), B (intermediate), and C (advanced) stages, is helpful by providing both 
prognostic prediction and treatment allocation, and therefore, it has been most widely 
Correspondence: Chai hong Rim
Department of Radiation Oncology, 
ansan hospital, Korea University, 
123 Jeokgeum-ro, Danwon-gu, ansan, 
gyeonggi-do 15355, Republic of Korea
Tel/fax +82 31 412 6850
email crusion3@naver.com
Journal name: Cancer Management and Research
Article Designation: Original Research
Year: 2019
Volume: 11
Running head verso: Lee et al
Running head recto: Lee et al
DOI: http://dx.doi.org/10.2147/CMAR.S193761
Cancer Management and Research 2019:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1374
lee et al
used.3,4 In BCLC staging system, BCLC stage C (BCLC C) 
encompasses heterogeneous populations, including patients 
with suboptimal performance status, portal invasion (PI), 
or extrahepatic nodal/distant spread among patients with 
preserved liver function of Child–Pugh Class A or B.5
Currently, for BCLC C, sorafenib is the only proven first-
line standard treatment according to two landmark random-
ized trials, Sorafenib HCC Assessment Randomized Protocol 
Trial (SHARP)6 and the Asia-Pacific Study,7 which reported 
median survival of 10.7 and 6.5 months, respectively, among 
advanced HCC patients. Although modest survival benefits 
are achieved, locoregional treatments are commonly used 
in clinic as significant tumor responses are rarely observed 
with sorafenib. Radiotherapy (RT) has been used emergently 
for BCLC C HCCs thanks to technological advances, and 
it helps to achieve significant tumor response (~60%) and 
sustained local control.8 Furthermore, recently, a randomized 
trial demonstrated that, for advanced HCC with macroscopic 
vascular invasion, first-line treatment with combined treat-
ment of transarterial chemoembolization (TACE) plus RT 
provided an increased progression-free survival and OS as 
compared with sorafenib.9
HCC is the second leading cause of cancer death in the 
Republic of Korea, with an incidence of 31 per 100,000 
population in the year 2015.10 In clinical practice, RT has 
been commonly used as an initial treatment for HCC, not 
only as a palliative treatment, but also for treating locally 
advanced tumors, and 22% of all HCC patients underwent 
RT in 2014.11,12 Hence, integrating clinical experiences of 
treating HCC in the Republic of Korea might be helpful to 
identify the role of local treatment including RT (LRT) as 
an initial treatment. Therefore, we conducted a nationwide 
population-based, retrospective cohort study to investigate 
the role of LRT among BCLC C patients in the real world, 
focusing on the oncologic outcomes in comparison with 
sorafenib.
Patients and methods
Database source
The Korean Ministry of Health and Welfare has initiated a 
project called Korean Central Cancer Registry (KCCR) since 
1980. The Korean Liver Cancer Study Group (KLCSG) and 
the National Cancer Center have extracted HCC patients’ 
records from the KCCR to settle the mother population, 
which have been assigned codes of C22.0 according to the 
ICD-10.
KLCSG performed projects three times (in the years 
2008–2010, 2011–2012, and 2013–2014), and 47, 50, and 51 
hospitals in the Republic of Korea were randomly selected 
among all hospitals nationwide which registered HCC 
patients in the KCCR. At least one hospital was selected 
from all 16 administrative districts in the Republic of Korea, 
and the probability proportional extraction method, which 
is more likely to select hospitals with a large number of 
registered patients, was used. Through three projects, the 
records of 10,580 patients who were initially diagnosed as 
HCC between 2008 and 2014 were sampled. This cohort 
represented 11.7% of all HCC patients registered in KCCR 
during the corresponding period.
Data on dates and causes of mortalities were obtained 
from the Korean Statistical Information Service. The date 
of the first diagnosis of HCC was provided in the data of 
the KCCR. Most recent follow-up date for survivors was 
December 31, 2016, and for those who were deceased, it 
was the time of death.
Our study design is schematically summarized in 
Figure 1.
study cohort
Of the 10,580 HCC patients, 3,401 patients (32.1%) were 
categorized as BCLC C. Among them, portal vein invasion 
was found in 1,980 patients (58.2%), lymph node metastasis 
(LNM) in 641 patients (18.8%), and distant metastasis (DM) 
in 892 patients (26.2%). The BCLC C patients who were 
treated with sorafenib, LRT, and no treatment as the “initial 
treatments” (the first treatment and the second treatment 
within 60 days after the first treatment) were included in 
the study. The term initial treatments was defined to exclude 
treatments for recurrence or progressed disease, but to 
encompass treatments for the initial disease at the primary 
clinical decision. The term “no treatment” denotes that 
the patient did not receive any of the treatments including 
surgery, radiofrequency ablation of ethanol injection, tran-
sarterial therapies, and chemotherapies including sorafenib 
at the initial decision. RT refers to external RT only, not 
selective internal RT or transarterial radioembolization 
using radioisotopes. LRT is defined as RT that is included 
as an initial treatment modality as first or second treatment. 
We used the term LRT rather than RT, as many RTs were 
performed in concordance with TACE and both modalities 
have the same treatment purpose as locoregional treatment. 
The patients were grouped according to their initial treatment 
modalities performed. Clinical factors including gender, 
age, hepatitis B, hepatitis C, Eastern Cooperative Oncology 
Group performance score, tumor size, PI, LNM, DM, and 
Child–Pugh score were analyzed.
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Outcome assessments and statistical 
analysis
The primary endpoint was OS. Also, we investigated relevant 
clinical variables related to OS. Chi-squared test was used for 
comparison of categorical variables among treatment groups, 
while ANOVA was used for comparison of continuous vari-
ables. Survival analyses were performed using Kaplan–Meier 
method, and log-rank test was used for intergroup com-
parison. For multivariate analysis, Cox proportional hazards 
model was used. All the statistical analyses were performed 
using SPSS v20.0 (IBM Corporation, Armonk, NY, USA).
ethical consideration
The data source of the present study is a public open data 
without personal identification information from KCCR, 
and the institutional review board approval was waived. 
Otherwise, we recognized and adhered to the World Medical 
Association Declaration of Helsinki.
Results
Patient characteristics
Among 3,401 HCC patients of BCLC C diagnosed from 2008 
to 2014, a total of 1,486 patients were included as they under-
went LRT, sorafenib, or no treatment as the initial treatment; 
the remaining patients were excluded as they did not meet 
the inclusion criteria (eg, underwent local treatments without 
RT, such as TACE, radiofrequency ablation, or surgery, or 
chemotherapy other than sorafenib). Of them, 266 (17.9%), 
316 (21.3%), and 904 (60.8%) were categorized as LRT, 
sorafenib, and no treatment group, respectively. Twenty-one 
patients who received both RT and sorafenib as the initial 
treatment were categorized in the LRT group.
Between LRT and sorafenib groups, two clinical factors 
out of eight including tumor size and DM were significantly 
different. Sorafenib group had more patients with the largest 
tumor size of >10 cm (56.0% vs 44.0%, P=0.006) and more 
patients with DM (50.6% vs 34.2%, P<0.001). A nonsig-
nificant trend of higher Child–Pugh score in the sorafenib 
group compared to LRT group (mean value: 6.24 [95% 
CI: 6.09–6.40] vs 5.94 [95% CI: 5.79–6.08], P=0.059) was 
found. TACE was combined as the initial treatment in 47.7% 
of the LRT group patients and 17.7% of the sorafenib group 
patients (P<0.001). In the LRT group, treatments other than 
RT or TACE which were performed as the initial treatments 
were 2 cases of surgical resection (0.7%), 1 case of liver 
transplantation (0.4%), 28 cases of chemotherapy other than 
sorafenib (10.5%), and 5 cases of chemotherapy (1.8%) with 
unreported regimen. In the sorafenib group, treatments other 
than sorafenib or TACE which were performed as the initial 
treatment were three cases of surgical resection (0.9%), one 
case of radiofrequency ablation (0.3%), and five cases of che-
motherapy other than sorafenib (1.6%). The characteristics 
of the patients categorized in the initial treatments groups 
are summarized in Table 1.
survival analyses
Results of univariate analyses related to survival according 
to treatment groups for all patients and each subgroup of 
patients by various factors are shown in Table 2 and Figure 2. 
Median follow-up time for survivors was 44.5 months. In 
univariate analysis, in the whole population, RT group 
showed superior OS at 12 months compared to sorafenib 
group (36.5% vs 17.7%, P<0.001; Figure 2A). Median OS 
was 7.6 months (range: 6.1–9.1) in the LRT group and 3.8 
Nationwide cancer
information recorded
at the Korean Central
Cancer Registry
10,580 patients were
randomly extracted by
the Korean Liver Cancer
Study Group
Study design
Inclusion criteria:
1. Treated with sorafenib or LRT as the initial
treatments*
2. Were decided to receive no treatment at
diagnosis
*Initial treatment: the first treatment and the second
treatment within 60 days after the first treatment
3,401 BCLC C
patients (32.1%)
were identified
Figure 1 schematic summary of the study design.
Abbreviations: BClC C, Barcelona Clinic of liver Cancer stage C; lRT, local treatment including radiotherapy.
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Table 1 Patients’ characteristics according to treatment groups
Variables LRT Sorafenib No treatment P-value
n=266 n=316 n=904 All groups RT vs sorafenib
Clinical factors
age
 Mean (95% Ci) 55.1 (53.8–56.5) 57.4 (56.1–58.7) 62.1 (61.3–63.0) <0.001 0.068
gender 0.231 0.389
 Male 222 (83.5%) 271 (86.0%) 740 (81.9%)
 Female 44 (16.5%) 44 (14.0%) 164 (18.1%)
hepatitis B <0.001 0.722
 Yes 191 (73.2%) 222 (71.8%) 373 (42.6%)
 no 70 (26.8%) 87 (28.2%) 502 (57.4%)
hepatitis C 0.036 0.132
 Yes 25 (10.0%) 19 (6.4%) 100 (11.7%)
 no 226 (90.0%) 276 (93.6%) 753 (88.3%)
eCOg 0.001 0.297
 0 119 (57.5%) 126 (50.2%) 296 (48.2%)
 1 75 (36.2%) 107 (42.6%) 226 (36.8%)
 2 13 (6.3%) 18 (7.2%) 92 (15.0%)
Tumor size, cm 0.022 0.006
 >10 117 (44.0%) 175 (55.4%) 445 (49.2%)
 ≤10 149 (56.0%) 141 (44.6%) 459 (50.8%)
Portal invasion 0.029 0.784
 Yes 196 (73.7%) 236 (74.7%) 613 (67.8%)
 no 70 (26.3%) 80 (25.3%) 291 (32.2%)
ln metastasis 0.289 0.343
 Yes 56 (21.1%) 77 (24.4%) 233 (25.8%)
 no 210 (78.9%) 239 (75.6%) 671 (74.2%)
Distant metastasis <0.001 <0.001
 Yes 91 (34.2%) 160 (50.6%) 323 (35.7%)
 no 175 (65.8%) 156 (49.4%) 581 (64.3%)
Child–Pugh score
 Mean (95% Ci) 5.94 (5.79–6.08) 6.24 (6.09–6.40) 6.68 (6.57–6.79) <0.001 0.059
Treatment factors
Combined TaCe <0.001
 Yes 127 (47.7%) 56 (17.7%)
 no 139 (52.3%) 260 (82.3%)
Abbreviations: eCOg, eastern Cooperative Oncology group performance score; ln, lymph node; lRT, locoregional treatment including radiotherapy; RT, radiotherapy; 
TaCe, transarterial chemoembolization.
months (range: 3.5–4.1) in the sorafenib group (P<0.001). 
No treatment group showed the worst median and 12-month 
OS rate for all patients (2.3 months and 15.2%, respectively). 
Median OS of 21 patients who underwent both RT and 
sorafenib was 6.6 months.
We performed the subgroup analysis by various variables 
such as with PI, with LNM, with and without DM, and 
presence of DM. In the subgroup analysis for the patients 
with PI (n=1,046), median OS and 12-month OS rates were 
7.5 months and 35.2%, respectively, in the LRT group and 
3.7 months and 14.8%, respectively, in the sorafenib group 
(P<0.001; Figure 2B). Furthermore, other three subgroup 
analyses for patients with LNM (n=366), without DM 
(n=913), and with DM (n=574) showed that LRT group had 
increased OS at 12 months compared to sorafenib group 
(33.9% vs 3.9%, Figure 2C; 40.6% vs 20.5 %, Figure 2D; 
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Figure 2 Overall survival according to treatment groups for all patients (A) and each subgroup of patients with portal invasion (B), lymph node metastasis (C), without 
distant metastasis (D), and with distant metastasis (E).
Abbreviation: lRT, locoregional treatment.
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and 28.6% vs 15.0%, Figure 2E, respectively; P<0.001 in 
all; Table 2). No treatment group showed the worst 12-month 
OS of 15.2% in all patients and also in the four subgroups 
of patients with PI (9.0%), with LNM (8.6%), without DM 
(20.0%), and with DM (6.5%).
In multivariable analysis, sorafenib group showed sig-
nificantly higher risk related to mortality LRT group, not 
only among all patients (HR: 1.50, 95% CI: 1.23–1.84, 
P<0.001), but also between subgroup cohorts with PI (1.55, 
95% CI: 1.23–1.96, P<0.001), with LNM (2.42, 95% CI: 
1.53–3.83, P<0.001), without DM (1.43, 95% CI: 1.10–
1.87, P=0.009), and with DM (1.57, 95% CI: 1.13–2.19, 
P=0.007). Further, no treatment group showed the lowest OS 
compared to other groups, not only among all patients, but 
also in each subgroup of patients with LNM, without DM, 
and with DM (P<0.001 in all; Table 3). Among all BCLC C 
patients, gender (P=0.002), performance status (P=0.005), 
tumor size (P<0.001), PI (P<0.001), lymph node (P<0.001) 
and distant metastases (P<0.001), and Child–Pugh score 
(P<0.001) were statistically significant, but not the age and 
viral profiles of hepatitis B and C. Multivariable analyses 
related to OS according to treatment groups for all patients 
and patients in subgroups by various factors are summarized 
in Table 3.
Discussion
Current nationwide cohort analysis of HCC patients of BCLC 
C showed that LRT was associated with a significantly longer 
OS compared with sorafenib as the initial treatment. This 
study implicated that LRT might be a significant treatment 
option in addressing an unmet need in treating advanced HCC 
patients with heterogeneity. To our knowledge, BCLC C is 
a heterogeneous population with various advanced features 
that lead to dismal prognosis.13 Although sorafenib, a multi-
tyrosine kinase inhibitor, has been approved as a standard sys-
temic therapy for patients with advanced HCC, the survival 
Table 2 Univariate analyses related to survival according to treatment groups for all patients and subgroups of patients by various 
factors
Variables LRT Sorafenib No treatment P-value
All groups RT vs sorafenib Sorafenib vs no 
treatment
All patients (N=1,486)
number of patients available 266 316 904
Median Os (95% Ci), months 7.6 (6.1–9.1) 3.8 (3.5–4.1) 2.3 (2.1–2.5)
12-month Os (se), % 36.5 (±3.0) 17.7 (±2.1) 15.2 (±1.2) <0.001 <0.001 <0.001
Subgroup of patients
With Pi (n=1,046)
 number of patients 196 236 613
 Median Os (95% Ci), months 7.5 (5.8–9.2) 3.7 (3.3–4.1) 2.1 (1.9–2.3)
 12-month Os (se), % 35.2 (±3.4) 14.8 (±2.3) 9.0 (±1.2) <0.001 <0.001 <0.001
With lnM (n=366)
 number of patients 56 77 233
 Median Os (95% Ci), months 7.1 (5.9–8.3) 3.3 (2.7–3.9) 1.8 (1.5–2.1)
 12-month Os (se), % 33.9 (±6.3) 3.9 (±2.2) 8.6 (±1.8) <0.001 <0.001 0.037
Without DM (n=913)
 number of patients 175 156 581
 Median Os (95% Ci), months 9.2 (6.7–11.7) 4.0 (3.2–4.8) 2.8 (2.4–3.2)
 12-month Os (se), % 40.6 (±3.7) 20.5 (±3.2) 20.0 (±1.7) <0.001 <0.001 0.044
With DM (n=574)
 number of patients 91 160 323
 Median Os (95% Ci), months 6.6 (5.5–7.7) 3.5 (3.0–4.0) 1.7 (1.5–1.9)
 12-month Os (se), % 28.6 (±4.7) 15.0 (±2.8) 6.5 (±1.4) <0.001 <0.001 <0.001
Abbreviations: DM, distant metastasis; ln, lymph node; lnM, lymph node metastasis; lRT, locoregional treatment; Os, overall survival; Pi, portal invasion; RT, radiation 
therapy; se, standard error.
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Table 3 Multivariable analysis related to survival for all patients and for subgroups of patients by various factors
Variables All patients With PI With LNM Without DM With DM
Exp (B) 
(95% CI)
P-value Exp (B) 
(95% CI)
P-value Exp (B) 
(95% CI)
P-value Exp (B) 
(95% CI)
P-value Exp (B) 
(95% CI)
P-value
agea ns 0.993 ns 0.814 ns 0.627 ns 0.746 ns 0.17
gender
 Female Reference Reference Reference Reference Reference
 Male 1.32  
(1.11–1.58)
0.002 1.27  
(1.02–1.59)
0.034 ns 0.443 1.43 
(1.15–1.78)
0.001 ns 0.303
eCOg Ps
 0 Reference Reference Reference Reference Reference
 1 1.03  
(0.89–1.19)
0.686 1.14  
(0.97–1.35)
0.12 ns 0.468 1.22 
(1.02–1.47)
0.034 ns 0.804
 2 1.36  
(1.10–1.69)
0.005 1.68  
(1.29–2.19)
<0.001 ns 0.025 1.79 
(1.36–2.36)
<0.001 ns 0.715
Tumor size, cm
 ≤10 Reference Reference Reference Reference Reference
 >10 1.49  
(1.29–1.71)
<0.001 1.35  
(1.16–1.59)
<0.001 ns 0.124 1.58 
(1.32–1.88)
<0.001 1.32 
(1.06–1.65)
0.014
Portal invasion
 no Reference na Reference Reference Reference
 Yes 1.80  
(1.54–2.11)
<0.001 1.37 
(1.01–1.85)
0.041 2.47 
(1.99–3.07)
<0.001 1.30 
(1.02–1.65)
0.036
ln metastasis
 no Reference Reference na Reference Reference
 Yes 1.46  
(1.24–1.72)
<0.001 1.32  
(1.07–1.62)
0.008 2.07 
(1.63–2.62)
<0.001 1.25 
(1.00–1.56)
0.052
Distant 
metastasis
 no Reference Reference Reference na na
 Yes 1.52  
(1.31–1.76)
<0.001 1.34  
(1.12–1.61)
0.002 ns 0.171
initial treatment
 lRT Reference Reference Reference Reference Reference
 sorafenib 1.50  
(1.23–1.84)
<0.001 1.55  
(1.23–1.96)
<0.001 2.42 
(1.53–3.83)
<0.001 1.43 
(1.10–1.87)
0.007 1.57 
(1.13–2.19)
0.007
  supportive 
care
2.12  
(1.77–2.54)
<0.001 2.40  
(1.95–2.96)
<0.001 3.06 
(2.01–4.65)
<0.001 1.86 
(1.49–2.31)
<0.001 2.73 
(1.99–3.76)
<0.001
hepatitis B
 no Reference Reference Reference Reference Reference
 Yes ns 0.479 ns 0.336 ns 0.267 ns 0.871 ns 0.896
heptatitis C
 no Reference Reference Reference Reference Reference
 Yes ns 0.375 ns 0.309 0.56 
(0.36–0.86)
0.008 ns 0.466 ns 0.596
CPC scorea 1.30  
(1.23–1.36)
<0.001 1.31  
(1.24–1.39)
<0.001 1.45 
(1.31–1.61)
<0.001 1.30 
(1.22–1.39)
<0.001 1.33 
(1.22–1.44)
<0.001
Notes: aContinuous value. ns means the variable is not included in the equation of Cox proportional hazard model.
Abbreviations: CPC, Child–Pugh score; DM, distant metastasis; eCOg Ps, eastern Cooperative Oncology group performance score; exp (B), exponential B; ln, lymph 
node; LNM, lymph node metastatis; LRT, local treatment including RT; NA, not applicable; NS, nonsignificant; PI, portal invasion; RT, radiation therapy.
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gain is modest and the tumor response is unsatisfactory. To 
overcome the heterogeneity and aggressiveness of such a 
disease, optimal therapeutic approaches are still required 
for further investigation. Thus, not only sorafenib, but also 
various treatment modalities including TACE, external RT, 
radioembolization, systemic chemotherapy, and combina-
tion therapy are being employed based on an empirical 
consequence. In particular, we found that many previous 
studies suggested that the incorporation of RT in multimodal 
approach enhances the survival outcome for patients with 
BCLC C HCC,14,15 and that the utilization of RT has increased 
for HCC, as the RT technique has remarkably developed,15,16 
although RT has lower evidence and recommendation level 
as the first-line treatment modality.
Also, our nationwide study suggested that for some 
patients with BCLC C HCC in real practice, sorafenib 
monotherapy may not be a unique and effective treatment 
modality. In HCC patients, the prediction of prognosis is 
complicated not only by the disease stages with heterogene-
ity, but also by the aspects of cirrhosis and underlying liver 
function with diversity affecting survival. Therefore, even 
well-designed trials could not include the various clinical 
situations due to these multiple factors, which contributed 
to the inconsistency of therapeutic efficacy between the 
controlled clinical trial and the community clinical setting.17 
Importantly, although randomization is the only reliable 
method to control for confounding factors when comparing 
treatment groups, it was noted that randomized trials have 
limitations that they involve only selected patients who are 
treated according to trial protocols that might not represent 
real-world practice.2,18,19 Notably, in both the SHARP trial 
and the Asia-Pacific trial with ~50%–70% of patients with 
extrahepatic spread,6,7 we observed that the survival benefits 
of sorafenib were not significant. Furthermore, the sorafenib 
group did not have improvement of OS in 35% of patients 
with macrovascular involvement in the Asia-Pacific trial.7 In 
other words, other therapy or combination therapies could be 
more effective than sorafenib alone for some patients with 
BCLC C HCC who met specific criteria from the protocol 
criteria of randomized trials.
Thus, many previous studies reported the result of 
other treatments compared with sorafenib monotherapy for 
advanced HCC.20–23 Among these, Choi et al reported that 
combination therapy including sorafenib and TACE resulted 
in a better OS compared with sorafenib monotherapy (8.9 
vs 5.9 months, P=0.009) in patients with BCLC C HCC 
using propensity score-based methods.20 Nakazawa et al 
reported two times longer median OS in the RT group when 
they compared survival following sorafenib in patients with 
unresectable HCC with portal vein tumor thrombosis (PVT) 
by propensity score matching analysis (10.9 vs 4.8 months; 
P=0.025).22 In agreement with this viewpoint, our nationwide 
cohort study, which had the strength of a large-scale all-
comers in a clinical setting,18 showed consistent results for 
the therapeutic superiority of LRT compared with sorafenib 
for HCC BCLC C disease.
This study revealed a significant effect of LRT in all 
subgroups with adverse features such as patients with PI, 
with LNM, and with/without DM compared to sorafenib. 
Among these, especially PI including PVT occurred in 
most advanced HCC patients and was associated with 
poor prognosis because of increased risk of tumor spread, 
elevated portal venous pressure, and decreased portal flow 
resulting in ascites, jaundice, hepatic encephalopathy, and 
liver failure.24,25 In our study, we observed that 68% of all 
patients had PI, and LRT contributed to improvement of OS 
in the subgroup of patients with PI, compared to sorafenib. 
Nakazawa et al demonstrated that RT was more effective 
than sorafenib, because PVT which is intensively irradi-
ated by RT might result in recanalization of the portal vein. 
Furthermore, other previous studies reported good treatment 
responses and promising outcomes using RT for PVT.26,27 
In its extension, in a recent randomized clinical trial, it was 
worthwhile to show that the efficacy and safety of RT with 
TACE was superior to those of sorafenib for HCC BCLC C 
with vascular invasion.9 Hence, it is suggested that the pres-
ence of PVT in advanced HCC may be one of the indicators 
for administration of initial LRT. In the future, LRT should 
be integrated into comprehensive treatment guidelines for 
advanced HCC with vascular involvement including PVT.
In subgroup analyses, the benefit of LRT as compared 
to sorafenib was most prominent for the patients with LNM 
(HR: 2.42, 95% CI: 1.53–3.83). Although the incidence 
is rare, LNM of HCC is known to have poor prognosis as 
DMs.28 LNMs can cause serious side effects such as obstruc-
tive jaundice, pyloric obstruction, and inferior vena cava 
obstruction.29 Wee et al30 reported that symptoms due to 
LNM might triple the risk of death in HCC patients. In the 
recent meta-analysis of studies regarding RT for HCC with 
LNM, the response rate was 73.1%, and it was 82.2% in the 
high-dose RT subgroup.31 The present study reinforces the 
utility of RT for HCC with LNM, in addition to the results 
of previous studies.
Although the strength of this study was the use of a nation-
wide population-based cohort analysis, there are several 
limitations. First, our retrospective cohort study has  potential 
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biases related to unmeasured or unknown confounding 
variables. Despite our scrupulous study design and control 
for confounding factors throughout multivariable analyses, 
these biases might have affected our results. The KCCR does 
not provide detailed information on the patient’s lifestyle or 
health-related factors, such as smoking history, alcohol con-
sumption, body mass index, and socioeconomic status, which 
can increase the risk of cancer and were potential confound-
ers. Another limitation is that we were unable to evaluate the 
complete use of RT or sorafenib. NCCR provided information 
only regarding whether RT or sorafenib was administered or 
not. In particular, the therapeutic effect and toxicity of RT are 
greatly affected by the radiation dose, and the advanced tech-
nique is known to have the potential to reduce this effect.32,33 
As the use of RT in HCC has not yet been accepted as a stan-
dard option, details of dose or RT methods are not available 
in the data source of this study. We do hope that the future 
data can include the treatment details of RT, so that further 
analysis is available to optimize application of RT for HCC. 
Additionally, the “no treatment” subgroup refers to patients 
who decided to undergo no treatment at first visit, and some 
of these might visit another hospital to gather second opinion 
to take any treatment.
Besides the limitations in the study design, our study 
did not reflect the effects of regorafenib or carbozantinib, 
which have been shown to improve survival as secondary 
treatments after sorafenib in a very recent trial.34,35 However, 
our study is about initial treatment, and the role of systemic 
treatment, including sorafenib and second-line drugs, is more 
crucial after LRT. The development of new systemic agents 
is an epoch-making event in the treatment of HCCs, and 
we hope that the combination of appropriate LRT with new 
systemic agents will greatly improve the treatment efficiency 
of advanced HCCs in the future.
Our study has the advantage of demonstrating real-
world clinical practice for BCLC C patients in the Republic 
of Korea. In addition, with the large number of patients, 
sufficient statistical power could be achieved on analyz-
ing various clinical situations of BCLC C. The study by 
Yoon et al9 was the first randomized study to demonstrate 
the survival benefit of LRT as an initial option in BCLC 
C patients, but the limitations were that each arm had as 
small as 45 patients and covered only patients with vascular 
invasions. The present study is able to claim the benefit of 
LRT in all BCLC C patients complementary to the study 
by Yoon et al.9
In conclusion, our nationwide population study showed 
that LRT as an initial treatment showed survival benefit as 
compared to sorafenib in BCLC C patients. In practice, owing 
to moderate efficacy of sorafenib, in recent years, local treat-
ment modalities including RT for HCC BCLC C stage have 
continued to be investigated in comparison with sorafenib 
monotherapy to overcome heterogeneous disease entity and 
its prognosis. Accordingly, future prospective, randomized, 
and controlled studies are warranted to compare the effec-
tiveness of diverse treatment modalities including RT and to 
incorporate them into a multidisciplinary treatment approach 
in conjunction with sorafenib.
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